Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06755281

Risk-stratified Testing for Safe Removal of Penicillin Allergy Labels

The aim of this clinical trial is to analyze the negative predictive capacity and safety of risk-stratified direct drug provocation tests for patients with self-reported penicillin allergies. Patients reporting immediate or delayed penicillin allergies and defined as low-risk by the PEN-FAST score will receive drug provocation tests without prior skin testing.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Heidelberg, Dermatology, Heidelberg, Baden-Wurttemberg, Germany

Loading trial locations.

About this study

The PEN-FAST clinical decision rule is an internationally validated scoring system (0-5 points) that identifies low-risk patients (= a score of 0-2 points) with self-reported penicillin allergies with a negative predictive value (NPV) of over 95%. Performing direct drug provocation tests without prior skin testing on these low-risk patients was shown to be non-inferior in terms of safety and prediction of immediate allergic reactions. However, several studies have questioned the negative predictive capacity of the PEN-FAST score. In these studies, misclassifications of the PEN-FAST score were mainly based on positive skin test findings that can show false-positive results.

This study aims to validate the NPV and safety of direct drug provocation tests using the PEN-FAST score.

Participants with a PEN-FAST score of 0-2 points will directly receive a two-dose challenge (50%-50%) or single challenge (100%) with the culprit penicillin and will be monitored for at least 4 hours. No skin tests will be performed prior to the drug provocation test. Patients will be instructed to contact the hospital after the drug provocation test to monitor any delayed allergic reactions.

The outcomes will be compared to those of patients with a PEN-FAST score of 0-2 points who do not wish to skip the skin tests and who will, in parallel, receive the standard-of-care testing.

Currently, this study is approved as a single-site study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult outpatients or inpatients with a penicillin allergy label
  • Willing and able to give consent.
  • PEN-FAST score of 0-2 points

Exclusion criteria

  • Age <18 years
  • Concurrent immunosuppressive therapy with 20 mg of prednisolone per day or steroid equivalent
  • Concurrent antihistamine therapy
  • Pregnancy
  • Significantly impaired general condition
  • Unstable or therapeutically inadequately controlled bronchial asthma
  • History of stem cell transplantation
  • History of acute interstitial nephritis
  • Chronic urticaria
  • Mastocytosis

Treatment and study plan

Direct Oral challenge

Other

Patients will receive a 1-step or 2-step challenge with the suspected penicillin and will be monitored for any allergic reaction within the first four hours. Patients will be instructed to contact the hospital after the drug provocation test to inquire delayed allergic reactions.

Standard of care

Other

The patient will receive skin prick test and patch test (if a delayed allergy is suspected). Allergen-specific IgE will be measured. If all negative, drug provocation tets will be performed identical to the experimental group.

Primary outcomes

  1. The difference in the proportion of patients with any positive finding in skin tests, allergen-specific IgE or drug provocation test between the two groups

    Time frame: 7 days

    Percentage of subjects that retain their allergy label as they show at least one positive finding in skin tests, allergen-specific IgE or drug provocation test.

Secondary outcomes

  1. Negative predictive capacity of skin tests and allergen-specific IgE

    Time frame: 7 days

    Negative predictive values of each test alone and combined

  2. Analysis of medical and allergic history

    Time frame: 1 day

    (supposed) allergic symptoms

  3. Penicillin allergy label

    Time frame: 1 day

    Identification of culprit penicillin

  4. Analysis of demographic data

    Time frame: 1 day

    Age, sex

  5. Analysis of adverse reactions

    Time frame: 7 days

    Detailed analysis of any (supposed) allergic reactions following drug provocation test

  6. Analysis of medical and allergic history

    Time frame: One day

    year of (supposed) allergic reaction

  7. Analysis of medical and allergic history

    Time frame: One day

    time between administration and (supposed) allergic reaction

  8. Analysis of medical and allergic history

    Time frame: One day

    treatment required for (supposed) allergic reaction

  9. Analysis of medical and allergic history

    Time frame: One day

    current medication

  10. Analysis of internal hospital risk stratification system

    Time frame: One day

    Measurement of score of internal hospital risk stratification system

  11. Analysis of medical and allergic history

    Time frame: One day

    (supposed) allergic symptoms

Study contacts

Contact information is provided by the study sponsor or research team.

Deniz Göcebe, MD

CONTACT

[email protected]

+4962215639539

Knut Schäkel, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

Deniz Göcebe

Other

Registry information

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jan 1, 2025
Registry last updated
Apr 10, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.